A method for large-scale implantation of 3D microdevice ensembles into brain and soft tissue

Implantable brain machine interfaces: first-in-human studies, technology challenges and trends

Implantable brain machine interfaces (BMIs) are now on a trajectory to go mainstream, wherein what was once considered last resort will progressively become elective at earlier stages in disease treatment. First-in-human successes have demonstrated the ability to decode highly dexterous motor skills such as handwriting, and speech from human cortical activity. These have been used for cursor and prosthesis control, direct-to-text communication and speech synthesis. Along with these breakthrough studies, technology advancements have enabled the observation of more channels of neural activity through new concepts for centralised/distributed implant architectures. This is complemented by research in flexible substrates, packaging, surgical workflows and data processing. New regulatory guidance and funding has galvanised the field. This culmination of resource, efforts and capability is now attracting significant investment for BMI commercialisation. This paper reviews recent developments and describes the paradigm shift in BMI development that is leading to new innovations, insights and BMI translation.

Tracking the Migration of Injectable Microdevices in the Rodent Brain Using a 9.4T Magnetic Resonance Imaging Scanner

Wirelessly powered microdevices are being miniaturized to improve safety, longevity, and spatial resolution in a wide range of biomedical applications. Some wireless microdevices have reached a point where they can be injected whole into the central nervous system. However, the state-of-the-art floating microdevices have not yet been tested in chronic brain applications, and there is a growing concern that the implants might migrate through neural tissue over time. Using a 9.4T MRI scanner, we attempt to address the migration question by tracking ultra-small devices injected in different areas of the brain (cortico-subcortical) of rats over 5 months. We demonstrate that injectable microdevices smaller than 0.01 mm³ remain anchored in the brain at the targeted injection site over this time period. Based on CD68 (microglia) and GFAP (astrocytes) immunoreactivity to the microdevice, we hypothesize that glial scar formation is preventing the migration of chronically implanted microdevices in the brain over time.

A simple method for implanting free-floating microdevices into the nervous tissue

Objective. Free-floating implantable neural interfaces are an emerging powerful paradigm for mapping and modulation of brain activity. Minuscule wirelessly-powered devices have the potential to provide minimally-invasive interactions with neurons in chronic research and medical applications. However, these devices face a seemingly simple problem-how can they be placed into nervous tissue rapidly, efficiently and in an essentially arbitrary location?Approach. We introduce a novel injection tool and describe a controlled injection approach that minimizes damage to the tissue.Main results.To validate the needle injectable tool and the presented delivery approach, we evaluate the spatial precision and rotational alignment of the microdevices injected into agarose, brain, and sciatic nerve with the aid of tissue clearing and MRI imaging. In this research, we limited the number of injections into the brain to four per rat as we are using microdevices that are designed for an adult head size on a rat model. We then present immunohistology data to assess the damage caused by the needle.Significance. By virtue of its simplicity, the proposed injection method can be used to inject microdevices of all sizes and shapes and will do so in a fast, minimally-invasive, and cost-effective manner. As a result, the introduced technique can be broadly used to accelerate the validation of these next-generation types of electrodes in animal models.